Right ventricular enlargement predicts responsiveness to tolvaptan in congestive heart failure patients with reduced ejection fraction

BACKGROUND: Tolvaptan is a vasopressin type 2 receptor antagonist used in heart failure (HF) with refractory diuretic resistance. However, since tolvaptan is also ineffective in some HF patients with reduced ejection fraction (HFrEF), the identification of responders is important. METHODS: The study...

Descripción completa

Detalles Bibliográficos
Autores principales: Nonin, Shinichi, Iwata, Shinichi, Ito, Asahiro, Tamura, Soichiro, Kitada, Ryoko, Kawai, Yu, Ishikawa, Sera, Doi, Atsushi, Hanatani, Akihisa, Yoshiyama, Minoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191974/
https://www.ncbi.nlm.nih.gov/pubmed/30345343
http://dx.doi.org/10.1016/j.ijcha.2018.09.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191974/
https://www.ncbi.nlm.nih.gov/pubmed/30345343
http://dx.doi.org/10.1016/j.ijcha.2018.09.008

Ejemplares similares